Menopausal symptom severity inversely related to HAART adherence

  • Cutimanco-Pacheco V & al.
  • Climacteric
  • 6 Dec 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Intensity of menopausal symptoms is inversely proportional to likelihood of lower highly active antiretroviral therapy (HAART) adherence in HIV-infected menopausal women.

Why this matters

  • Consider comprehensive, multidisciplinary evaluation in middle-aged HIV-positive women experiencing moderate-to-severe menopausal symptoms to address common disease/condition or drug-related factors driving nonadherence (e.g., sleep disorders, vasomotor/musculoskeletal complaints).

Key results

  • 313 included; median age, 47 years.

  • 91.5%, 8.5% reported natural, surgical postmenopause, respectively.

  • 19.8%, 32.6%, 15.0% had mild, moderate, severe menopausal symptoms, respectively.

  • 70.6% were nonadherent (25.6%, 45.0%, low, insufficient, respectively) vs 29.4% adherent (24.3%, 5.1%, adequate, strict, respectively).

  • Nonadherence rate was 45.1%, 80.7%, 79.4%, 93.6% for women with no, mild, moderate, severe symptoms, respectively.

  • Total Menopause Rating Scale score higher in non- vs adherent women (P<.001>

  • HAART nonadherence probability, adjusted prevalence ratio (aPR), statistical model (a 1 PR [95% CI]): mild, 1.80 [1.41-2.29]; moderate, 1.72 [1.36-2.18]; severe, 2.06 [1.64-2.29]).

  • Epidemiological model (a 2 PR [95% CI]): mild, 1.84 (1.45-2.34); moderate, 1.83 (1.44-2.32); severe, 2.17 (1.73-2.73).

Study design

  • Cross-sectional study evaluating the association between menopausal symptoms and HAART adherence in middle-aged Peruvian women with menopausal symptoms, January 2016-December 2017.

  • Funding: None.

Limitations

  • Cross-sectional design. 

  • Nongeneralisable. 

  • Measurement bias.